JX-929
AXP000097.1 · Oncolytic virus
- Platform
- vaccinia virus (Western Reserve, TK- VGF-)
- Originator
- University of Pittsburgh (David Bartlett)
- Sponsor
- Jennerex Biotherapeutics
Names
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Western Reserve
- Replication
- conditionally replicating
- Modifications
- J2R (thymidine kinase) and C11R (vaccinia growth factor) both deleted
- Transgenes
- cytosine deaminase, SSTR2
- Route
- intratumoral, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C74089
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | Completed | Phase 1 | 2008-05 | 2013-01 | 26 | Breast Cancer; Colorectal Cancer; Head and Neck Squamous Cell Cancer; Liver Cancer; Melanoma; Pancreatic Adenocarcinoma |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors | Recruiting | Phase 1 | 2025-05-06 | 2028-04 | 18 | Esophageal Cancer; Gastric Adenocarcinoma; Gastric Cancer; Gastric Neoplasms; Liver Cancer; Liver Metastasis; MSI-H; MSS; MSS-CRC; Peritoneal Cancer; Peritoneal Carcinoma; Peritoneal Metastases | name in intervention: vvDD |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 27203445 | Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. | Molecular therapy : the journal of the American Society of Gene Therapy | 2016 | name in title: vvDD |
Notes
The 'double-deleted' vaccinia vvDD armed with cytosine deaminase and the somatostatin receptor; phase 1 by intratumoral and intravenous injection (NCT00574977). The unarmed vvDD backbone is a platform, not a separate program here. A cell-carrier form (autologous CIK cells loaded with vvDD-CDSR, CRX100, NCIt C179187) is a different product and is not entered.
How to cite
JX-929 (AXP000097.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000097.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.